peginesatide acetate · Takeda Pharms Usa · NDA 202799

Omontys Preservative Free

Earliest generic entry, as listed · earliest of 6 marketed strengths
Open now

No marketed reference-listed strength; date taken from all listed strengths.

No unexpired patents or exclusivities are listed for this product.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 6

NDA · productFormStrengthListed expiry
202799 · 001 · discontinuedsolution, intravenous, subcutaneousEQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)open
202799 · 002 · discontinuedsolution, intravenous, subcutaneousEQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)open
202799 · 003 · discontinuedsolution, intravenous, subcutaneousEQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)open
202799 · 004 · discontinuedsolution, intravenous, subcutaneousEQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)open
202799 · 005 · discontinuedsolution, intravenous, subcutaneousEQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)open
202799 · 006 · discontinuedsolution, intravenous, subcutaneousEQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)open
Expired or delisted (2)
  • US 7550433 · use U-1238 · 2 Jun 2026
  • US 7919461 · use U-1238 · 2 Jun 2026